scispace - formally typeset
K

Kari Alitalo

Researcher at University of Helsinki

Publications -  844
Citations -  122462

Kari Alitalo is an academic researcher from University of Helsinki. The author has contributed to research in topics: Angiogenesis & Vascular endothelial growth factor C. The author has an hindex of 174, co-authored 817 publications receiving 114231 citations. Previous affiliations of Kari Alitalo include Mount Sinai Hospital, Toronto & Cornell University.

Papers
More filters
Journal ArticleDOI

MMP16 Mediates a Proteolytic Switch to Promote Cell–Cell Adhesion, Collagen Alignment, and Lymphatic Invasion in Melanoma

TL;DR: A novel mechanism in melanoma pathogenesis is uncovered, whereby restricted collagen infiltration and limited mesenchymal invasion are unexpectedly associated with the properties of the most aggressive tumors, revealing MMP16 as a putative indicator of adverse melanoma prognosis.
Journal ArticleDOI

Structural and functional specificity of FGF receptors

TL;DR: The molecular cloning of the signal transducing receptors for fibroblast growth factors has revealed a tyrosine kinase gene family with at least four members, and the dual receptor system for FGFs might be an example of a more widely used principle.
Journal ArticleDOI

A fluorescent Tie1 reporter allows monitoring of vascular development and endothelial cell isolation from transgenic mouse embryos

TL;DR: Transgenic mice expressing enhanced green fluorescent protein (EGFP) or a chimeric protein consisting of a Zeosin resistance marker and EGFP under the control of mouse Tie1 promoter establish Tie1‐Z/EGFP transgenic mice as a useful model to study embryonic vascular development and a convenient source for the isolation of primary endothelial cells.
Journal ArticleDOI

The Basis for the Distinct Biological Activities of Vascular Endothelial Growth Factor Receptor–1 Ligands

TL;DR: It is shown that VEGF-B, unlike other VEGFs, did not require D3 interactions for high-affinity binding, and this may aid in designing VEGFR-1–targeting compounds that can inhibit or stimulate angiogenesis.